We are live on ! Find out more
ARMP icon

Armata Pharmaceuticals
ARMP

24 hedge funds and large institutions have $843K invested in Armata Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

5% less capital invested

Capital invested by funds: $886K → $843K (-$43K)

8% less funds holding

Funds holding: 26 → 24 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
24
Holders Change
-2
Holders Change %
-7.69%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$53.1K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$47.2K
3
VF
Virtu Financial
New York
+$28.4K
4
Citadel Advisors
Citadel Advisors
Florida
+$7.33K
5
SWP
Stratos Wealth Partners
Ohio
+$5.22K

Top Sellers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$46K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$36K
3
ARTA
A.R.T. Advisors
New York
-$11K
4
UBS Group
UBS Group
Switzerland
-$6.04K
5
PAM
Panagora Asset Management
Massachusetts
-$2.1K

ARMP Hedge Fund Activity: Q3 2018 in Review

24 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q3 2018, worth a combined $843K — down 4.9% from $886K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ARMP and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 5 added.

The largest buyer was Renaissance Technologies, adding an estimated $53.1K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $46K sold.

  • 24 institutional investors held Armata Pharmaceuticals (ARMP) as of Q3 2018, down from 26 in Q2 2018.
  • Funds reported $843K of Armata Pharmaceuticals stock for Q3 2018, down 4.9% quarter-over-quarter.
  • 2 funds opened new Armata Pharmaceuticals positions in Q3 2018 and 4 closed out, a net change of -2 holders.
  • The largest Armata Pharmaceuticals buyer in Q3 2018 was Renaissance Technologies, an estimated $53.1K added.
  • The largest Armata Pharmaceuticals seller in Q3 2018 was Acadian Asset Management, an estimated $46K sold.

Based on aggregated 13F filings for Q3 2018.